Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pacira Pharm Inc
(NQ:
PCRX
)
14.50
+0.17 (+1.19%)
Streaming Delayed Price
Updated: 12:52 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pacira Pharm Inc
< Previous
1
2
3
4
Next >
Earnings Preview: Pacira BioSciences
November 01, 2023
Via
Benzinga
Analyst Expectations for Pacira BioSciences's Future
October 23, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
September 11, 2023
Monday's session saw 175 companies set new 52-week lows.
Via
Benzinga
4 Analysts Have This to Say About Pacira BioSciences
August 03, 2023
Via
Benzinga
Analyst Ratings for Pacira BioSciences
July 13, 2023
Via
Benzinga
Looking Into Pacira BioSciences's Return On Capital Employed
May 09, 2023
Via
Benzinga
Recap: Pacira BioSciences Q1 Earnings
May 03, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
What 6 Analyst Ratings Have To Say About Pacira BioSciences
April 20, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 08, 2023
Friday's session saw 225 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
August 03, 2023
Via
Benzinga
Why Pacira BioSciences Shares Are Trading Lower Today
May 03, 2023
Pacira BioSciences Inc (NASDAQ: PCRX) reported Q1 sales of $160.3 million compared to $158.0 million a year ago and the
Via
Benzinga
Analyst Expectations for Pacira BioSciences's Future
February 28, 2023
Via
Benzinga
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Earnings Preview For Pacira BioSciences
February 27, 2023
Via
Benzinga
Where Pacira BioSciences Stands With Analysts
January 31, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
January 23, 2023
On Monday, 12 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
January 10, 2023
Tuesday's session saw 16 companies set new 52-week lows.
Via
Benzinga
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
December 13, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
December 13, 2022
On Tuesday, 49 companies hit new 52-week lows.
Via
Benzinga
Pacira BioSciences's Return On Capital Employed Insights
November 23, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
November 16, 2022
On Wednesday, 70 companies set new 52-week lows.
Via
Benzinga
Pacira BioSciences: Q3 Earnings Insights
November 03, 2022
Pacira BioSciences (NASDAQ:PCRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
October 07, 2022
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.
Via
Investor's Business Daily
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery
September 21, 2022
Via
Benzinga
Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug
September 07, 2022
Via
Benzinga
Pacira BioSciences' Return On Capital Employed Overview
August 08, 2022
Via
Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Pacira BioSciences: Q2 Earnings Insights
August 03, 2022
Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement.
Via
Benzinga
Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know
June 15, 2022
Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.